HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Lomustine (CCNU)

An alkylating agent of value against both hematologic malignancies and solid tumors.

Also Known As:

CCNU; CeeNU; Belustine; Bristol-Myers Squibb Brand of Lomustine; Cecenu; NSC-79037; Rhône-Poulenc Rorer Brand of Lomustine; medac Brand of Lomustine; Bristol Myers Squibb Brand of Lomustine; Lomustine medac Brand; NSC 79037; NSC79037; Rhône Poulenc Rorer Brand of Lomustine; Urea, N-(2-chloroethyl)-N'-cyclohexyl-N-nitroso-

Networked: 879 relevant articles (66 outcomes, 195 trials/studies)

Relationship Network

Drug Context: Research Results

Organic Chemicals: 58
- Urea: 9142
  - Nitrosourea Compounds: 16
    - Lomustine: 879
- Nitroso Compounds: 319
  - Nitrosourea Compounds: 16
    - Lomustine: 879

Experts

1.	van den Bent, Martin J: 20 articles (12/2015 - 02/2005)
2.	Weller, Michael: 12 articles (10/2014 - 05/2002)
3.	Brandes, Alba A: 10 articles (05/2014 - 02/2003)
4.	Taphoorn, Martin J B: 9 articles (07/2015 - 06/2006)
5.	Kros, Johan M: 9 articles (01/2015 - 02/2005)
6.	Gorlia, Thierry: 9 articles (11/2013 - 06/2006)
7.	Wick, Wolfgang: 8 articles (01/2015 - 09/2006)
8.	van den Bent, M J: 7 articles (07/2015 - 01/2001)
9.	Buckner, Jan C: 7 articles (03/2014 - 01/2003)
10.	Lacombe, Denis: 7 articles (11/2013 - 06/2006)

Related Diseases

1.	Neoplasms (Cancer) 07/01/1978 - "We conclude that autologous bone marrow support may allow the use of high-dose CCNU regimens and thereby increase its therapeutic efficacy in the treatment of advanced cancer." 07/01/2002 - "Hematological toxicity and therapeutic efficacy of lomustine in 20 tumor-bearing cats: critical assessment of a practical dosing regimen." 09/01/1984 - "Such changes may result in improved response rates as it is possible to achieve in man, plasma and tumor levels of BENZO, which in the mouse model produce effective enhancement of the response to CCNU. " 07/01/2011 - "Prospective randomized clinical trial assessing the efficacy of Denamarin for prevention of CCNU-induced hepatopathy in tumor-bearing dogs." 01/01/2011 - "LCNPs greatly inhibited the growth of the L132 cancer cell line used in this study in comparison to the native Lomustine (LMT)."
2.	Glioma (Gliomas) 12/01/2002 - "Surgical resection with the placement of lomustine-releasing wafers is the only therapy proven in randomized trials to be beneficial for recurrent malignant gliomas. " 08/01/1978 - "Effect of CCNU on survival rate of objective remission and duration of free interval in patients with malignant brain glioma--final evaluation. " 01/01/1976 - "Effect of CCNU on survival, rate of objective remission and duration of free interval in patients with malignant brain glioma--first evaluation." 01/01/2006 - "In this study, for the first time in high grade malignant glioma, two orally administrated drugs were associated .TMZ 75 mg/m2 for 28 consecutive days and CCNU 100 mg/m2 on day 1 of every 6 weeks could be recommended as a safe treatment dosage. " 07/01/1973 - "EORTC protocol for the study of CCNU in the treatment of irradiated, operated, malignant glioma of the brain."
3.	Glioblastoma (Glioblastoma Multiforme) 03/01/2015 - "In this study, using glioblastoma cell lines, the authors investigated the anticancer effects of lomustine, alone and in combination with docosahexaenoic acid (DHA), an omega-3 polyunsaturated fatty acid normally abundant in the brain and known for its anticancer potential. " 03/01/2015 - "Taken together, these data suggest a potential role for a combination therapy of lomustine and DHA for the treatment of glioblastomas." 03/01/2015 - "Similar to the U87-MG observations, the combination of DHA and lomustine resulted in growth inhibition of 2 additional human-derived glioblastoma cell lines, DB029 and MHBT161. " 03/01/2015 - "Enhanced anticancer properties of lomustine in conjunction with docosahexaenoic acid in glioblastoma cell lines." 04/01/2011 - "Thirty-eight patients with glioblastoma were treated with the lomustine-based regimen, and five received the TMZ-based regimen. "
4.	Hodgkin Disease (Hodgkin's Disease) 07/01/1983 - "CCNU toxicity after an overdose in a patient with Hodgkin's disease. " 05/01/1983 - "The alternative drug regimen of CCNU-VP appears to be as effective as MOPP in producing CR and long-term survival in patients with advanced Hodgkin's disease." 07/01/1983 - "An overdose of CCNU (600 mg over a 15-d period) was unintentionally ingested by a patient with advanced Hodgkin's disease subjected to combination chemotherapy. " 11/01/1996 - "We describe a 46-year-old man with Hodgkin's disease in whom neutrophilic eccrine hidradenitis developed after each of the first two treatments with lomustine. " 01/01/1981 - "In a randomized study, the effect of single agent therapy, with CCNU was compared with that of BCNU in previously treated patients with advanced Hodgkin's disease. "
5.	Lymphoma (Lymphomas) 09/01/1999 - "CCNU is effective in the treatment of relapsed lymphoma." 07/01/2015 - "Two of five canine lymphoma cell lines required higher concentrations of lomustine to inhibit cell growth by 50%, but their sensitivity to the drug increased when they were cultured with an MGMT inhibitor. " 10/01/2012 - "Lomustine has an acceptable efficacy and safety for use as a rescue agent in feline lymphoma." 10/01/2012 - "This retrospective study evaluated the use of lomustine as a rescue agent for 39 cases of resistant feline lymphoma. " 10/01/2012 - "Evaluation of lomustine as a rescue agent for cats with resistant lymphoma."

Related Drugs and Biologics

1.	Vincristine (Oncovin)
2.	Procarbazine (Matulane)
3.	Lomustine (CCNU)
4.	Carmustine (FIVB)
5.	Vinblastine (Vinblastine Sulfate)
6.	Doxorubicin (Adriamycin)
7.	Bleomycin (Blenoxane)
8.	Prednisone (Sone)
9.	temozolomide (Temodar)
10.	Cyclophosphamide (Cytoxan)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Radiotherapy
3.	Combination Drug Therapy (Combination Chemotherapy)
4.	Bone Marrow Transplantation (Transplantation, Bone Marrow)
5.	Heterologous Transplantation (Xenotransplantation)